+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Osteogenesis Imperfecta - Pipeline Review, H1 2019

  • ID: 4760843
  • Drug Pipelines
  • 54 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Bone Therapeutics SA
  • Genzyme Corp
  • Mereo Biopharma Group Plc
  • SOM Biotech SL
  • MORE
Osteogenesis Imperfecta - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Osteogenesis Imperfecta - Pipeline Review, H1 2019, provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break easily, often from little or no apparent cause. This disease is caused by a defect, or flaw, in the gene that produces type 1 collagen, a protein used to create bone. Symptoms include bone deformities, multiple broken bones, loose joints, weak teeth, heart defects and respiratory problems. Treatment includes bisphosphonates and surgery.

Report Highlights

This latest pipeline guide Osteogenesis Imperfecta - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteogenesis Imperfecta (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteogenesis Imperfecta (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Bone Therapeutics SA
  • Genzyme Corp
  • Mereo Biopharma Group Plc
  • SOM Biotech SL
  • MORE
Introduction

Report Coverage

Osteogenesis Imperfecta - Overview

Osteogenesis Imperfecta - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Osteogenesis Imperfecta - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteogenesis Imperfecta - Companies Involved in Therapeutics Development

Amgen Inc

Bone Therapeutics SA

Genzyme Corp

Mereo Biopharma Group Plc

SOM Biotech SL

Osteogenesis Imperfecta - Drug Profiles

ALLOB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Osteogenesis Imperfecta - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fresolimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setrusumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Osteogenesis Imperfecta - Dormant Projects

Osteogenesis Imperfecta - Discontinued Products

Osteogenesis Imperfecta - Product Development Milestones

Featured News & Press Releases

Oct 15, 2018: Completion of patient enrolment in phase 2b study of BPS-804 for the treatment of osteogenesis imperfecta

Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to Treat Osteogenesis Imperfecta

May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study in patients with osteogenesis imperfecta, an orphan disease

Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme

Jun 30, 2016: Mereo’s BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta

Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for osteogenesis imperfecta

Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Osteogenesis Imperfecta, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Osteogenesis Imperfecta - Pipeline by Amgen Inc, H1 2019

Osteogenesis Imperfecta - Pipeline by Bone Therapeutics SA, H1 2019

Osteogenesis Imperfecta - Pipeline by Genzyme Corp, H1 2019

Osteogenesis Imperfecta - Pipeline by Mereo Biopharma Group Plc, H1 2019

Osteogenesis Imperfecta - Pipeline by SOM Biotech SL, H1 2019

Osteogenesis Imperfecta - Dormant Projects, H1 2019

Osteogenesis Imperfecta - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Osteogenesis Imperfecta, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen Inc
  • Bone Therapeutics SA
  • Genzyme Corp
  • Mereo Biopharma Group Plc
  • SOM Biotech SL
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760843
Adroll
adroll